OBJECTIVE: Apolipoprotein A-I (apoAI) acts as an ABCA1-dependent acceptor of cellular phospholipids and cholesterol during the biogenesis of HDL, but this activity is susceptible to oxidative inactivation by myeloperoxidase. We tried to determine which residues mediated this inactivation and create an oxidant-resistant apoAI variant. METHODS AND RESULTS: Mass spectrometry detected the presence of tryptophan, methionine, tyrosine, and lysine oxidation in apoAI recovered from human atheroma. We investigated the role of these residues in the myeloperoxidase-mediated loss of apoAI activity. Site-directed mutagenesis and chemical modification were used to create variants of apoAI which were tested for ABCA1-dependent cholesterol acceptor activity and oxidative inactivation. We previously reported that tyrosine modification is not required for myeloperoxidase-induced loss of apoAI function. Lysine methylation did not alter the sensitivity of apoAI to myeloperoxidase, whereas site-specific substitution of apoAI methionine to valine increased the sensitivity of apoAI to myeloperoxidase. ApoAI tryptophan residues were identified as essential in apoAI function and oxidant sensitivity as substitution of all four apoAI tryptophan residues to leucine led to loss of function, but the conservative substitution to phenylalanine retained full function and was resistant to oxidative inactivation. CONCLUSIONS: Tryptophan modification of apoAI is primarily responsible for the myeloperoxidase-mediated loss of the cholesterol acceptor activity of apoAI.
OBJECTIVE:Apolipoprotein A-I (apoAI) acts as an ABCA1-dependent acceptor of cellular phospholipids and cholesterol during the biogenesis of HDL, but this activity is susceptible to oxidative inactivation by myeloperoxidase. We tried to determine which residues mediated this inactivation and create an oxidant-resistant apoAI variant. METHODS AND RESULTS: Mass spectrometry detected the presence of tryptophan, methionine, tyrosine, and lysine oxidation in apoAI recovered from humanatheroma. We investigated the role of these residues in the myeloperoxidase-mediated loss of apoAI activity. Site-directed mutagenesis and chemical modification were used to create variants of apoAI which were tested for ABCA1-dependent cholesterol acceptor activity and oxidative inactivation. We previously reported that tyrosine modification is not required for myeloperoxidase-induced loss of apoAI function. Lysine methylation did not alter the sensitivity of apoAI to myeloperoxidase, whereas site-specific substitution of apoAImethionine to valine increased the sensitivity of apoAI to myeloperoxidase. ApoAItryptophan residues were identified as essential in apoAI function and oxidant sensitivity as substitution of all four apoAItryptophan residues to leucine led to loss of function, but the conservative substitution to phenylalanine retained full function and was resistant to oxidative inactivation. CONCLUSIONS:Tryptophan modification of apoAI is primarily responsible for the myeloperoxidase-mediated loss of the cholesterol acceptor activity of apoAI.
Authors: Constanze Bergt; Subramaniam Pennathur; Xiaoyun Fu; Jaeman Byun; Kevin O'Brien; Thomas O McDonald; Pragya Singh; G M Anantharamaiah; Alan Chait; John Brunzell; Randolph L Geary; John F Oram; Jay W Heinecke Journal: Proc Natl Acad Sci U S A Date: 2004-08-23 Impact factor: 11.205
Authors: Lemin Zheng; Benedicta Nukuna; Marie-Luise Brennan; Mingjiang Sun; Marlene Goormastic; Megan Settle; Dave Schmitt; Xiaoming Fu; Leonor Thomson; Paul L Fox; Harry Ischiropoulos; Jonathan D Smith; Michael Kinter; Stanley L Hazen Journal: J Clin Invest Date: 2004-08 Impact factor: 14.808
Authors: Steven E Nissen; Taro Tsunoda; E Murat Tuzcu; Paul Schoenhagen; Christopher J Cooper; Muhammad Yasin; Gregory M Eaton; Michael A Lauer; W Scott Sheldon; Cindy L Grines; Stephen Halpern; Tim Crowe; James C Blankenship; Richard Kerensky Journal: JAMA Date: 2003-11-05 Impact factor: 56.272
Authors: Jonathan D Smith; Wilfried Le Goff; Megan Settle; Gregory Brubaker; Christine Waelde; Andrew Horwitz; Michael N Oda Journal: J Lipid Res Date: 2004-01-01 Impact factor: 5.922
Authors: Subramaniam Pennathur; Constanze Bergt; Baohai Shao; Jaeman Byun; Sean Y Kassim; Pragya Singh; Pattie S Green; Thomas O McDonald; John Brunzell; Alan Chait; John F Oram; Kevin O'brien; Randolph L Geary; Jay W Heinecke Journal: J Biol Chem Date: 2004-08-02 Impact factor: 5.157
Authors: Roman Shchepin; Matias N Möller; Hye-young H Kim; Duane M Hatch; Silvina Bartesaghi; Balaraman Kalyanaraman; Rafael Radi; Ned A Porter Journal: J Am Chem Soc Date: 2010-11-19 Impact factor: 15.419
Authors: Andrzej Witkowski; Gary K L Chan; Jennifer C Boatz; Nancy J Li; Ayuka P Inoue; Jaclyn C Wong; Patrick C A van der Wel; Giorgio Cavigiolio Journal: FASEB J Date: 2018-01-17 Impact factor: 5.191
Authors: Stela Z Berisha; Greg Brubaker; Takhar Kasumov; Kimberly T Hung; Patricia M DiBello; Ying Huang; Ling Li; Belinda Willard; Katherine A Pollard; Laura E Nagy; Stanley L Hazen; Jonathan D Smith Journal: J Lipid Res Date: 2015-01-05 Impact factor: 5.922
Authors: Joseph A DiDonato; Kulwant Aulak; Ying Huang; Matthew Wagner; Gary Gerstenecker; Celalettin Topbas; Valentin Gogonea; Anthony J DiDonato; W H Wilson Tang; Ryan A Mehl; Paul L Fox; Edward F Plow; Jonathan D Smith; Edward A Fisher; Stanley L Hazen Journal: J Biol Chem Date: 2014-02-20 Impact factor: 5.157
Authors: Maryam Zamanian-Daryoush; Valentin Gogonea; Anthony J DiDonato; Jennifer A Buffa; Ibrahim Choucair; Bruce S Levison; Randall A Hughes; Andrew D Ellington; Ying Huang; Xinmin S Li; Joseph A DiDonato; Stanley L Hazen Journal: J Biol Chem Date: 2020-02-25 Impact factor: 5.157